DE60032739D1 - Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung - Google Patents

Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung

Info

Publication number
DE60032739D1
DE60032739D1 DE60032739T DE60032739T DE60032739D1 DE 60032739 D1 DE60032739 D1 DE 60032739D1 DE 60032739 T DE60032739 T DE 60032739T DE 60032739 T DE60032739 T DE 60032739T DE 60032739 D1 DE60032739 D1 DE 60032739D1
Authority
DE
Germany
Prior art keywords
cancer
immunoliposome
antibody fragment
compositions
systemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032739T
Other languages
English (en)
Other versions
DE60032739T2 (de
Inventor
Liang Xu
Cheng-Cheng Huang
William Alexander
Wenhua Tang
H Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
SynerGene Therapeutics Inc
Original Assignee
Georgetown University
SynerGene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, SynerGene Therapeutics Inc filed Critical Georgetown University
Publication of DE60032739D1 publication Critical patent/DE60032739D1/de
Application granted granted Critical
Publication of DE60032739T2 publication Critical patent/DE60032739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60032739T 1999-02-22 2000-02-22 Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung Expired - Lifetime DE60032739T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12113399P 1999-02-22 1999-02-22
US121133P 1999-02-22
PCT/US2000/004392 WO2000050008A2 (en) 1999-02-22 2000-02-22 Antibody fragment-targeted immunoliposomes for systemic gene delivery

Publications (2)

Publication Number Publication Date
DE60032739D1 true DE60032739D1 (de) 2007-02-15
DE60032739T2 DE60032739T2 (de) 2007-05-24

Family

ID=22394769

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032739T Expired - Lifetime DE60032739T2 (de) 1999-02-22 2000-02-22 Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung

Country Status (11)

Country Link
US (3) US7479276B1 (de)
EP (3) EP1811036B8 (de)
JP (2) JP4799736B2 (de)
AT (2) ATE350012T1 (de)
AU (1) AU3703100A (de)
CA (1) CA2362550C (de)
DE (1) DE60032739T2 (de)
ES (2) ES2366100T3 (de)
HK (1) HK1106952A1 (de)
PT (1) PT1811036E (de)
WO (1) WO2000050008A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
DE10061110B4 (de) * 2000-12-07 2006-12-21 Schaller, Gerhard, Prof. Dr. med. Expression der Keratingene 8 und 18 zur Therapie von Tumoren, insbesondere des Mammakarzinoms
ES2312608T3 (es) * 2001-04-02 2009-03-01 Georgetown University Procedimiento simplificado y mejorado para preparar un polipejo o inmunoliposoma dirigido contra un anticuerpo o un fragmento de anticuerpo para la administracion sistemica de un agente de diagnostico o terapeutico.
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
CA2513769A1 (en) * 2003-01-28 2004-08-12 Georgetown University Method for evaluating the efficacy of certain cancer treatments
US20050002998A1 (en) * 2003-06-04 2005-01-06 Georgetown University Method for improving stability and shelf-life of liposome complexes
JP5478886B2 (ja) * 2005-10-20 2014-04-23 ジョージタウン・ユニバーシティ 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系
JP5336853B2 (ja) 2005-11-02 2013-11-06 プロチバ バイオセラピューティクス インコーポレイティッド 修飾ｓｉＲＮＡ分子およびその使用法
WO2007142781A1 (en) 2006-05-15 2007-12-13 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
KR101570886B1 (ko) * 2007-07-09 2015-11-23 조지타운 유니버시티 양이온성-리포솜 매개된 핵산 전달을 이용하여 면역 반응을 생성시키는 방법
JP4934531B2 (ja) * 2007-07-11 2012-05-16 株式会社日立製作所 アナログデジタル変換器及びその制御方法並びに無線トランシーバ回路
WO2009020094A1 (ja) * 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited 疎水性分子で修飾した抗体
EP2238251B1 (de) 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing der polo-like-kinase-expression unter verwendung von interferenz-rna
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011160062A2 (en) 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
DK2670843T3 (en) 2011-02-03 2015-01-05 Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUS
EP2780456A1 (de) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutische rna schalter-zusammensetzungen und anwendungsverfahren dafür
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
AU2013200991B2 (en) * 2012-09-19 2015-12-10 Georgetown University Targeted liposomes
WO2014046630A1 (en) 2012-09-19 2014-03-27 Keskin, Dilek Tumor targeted liposomal drug delivery system
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
CN105163762B (zh) 2013-03-14 2019-06-25 乔治敦大学 对神经毒剂的暴露的治疗
BR112017006679A2 (pt) 2014-10-02 2017-12-26 Protiva Biotherapeutics Inc moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
JP3215716U (ja) 2015-04-09 2018-04-12 ビカンタ コーポレイション 蛍光ナノダイヤモンドを使用した撮像システムおよびその方法
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
EP3329003A2 (de) 2015-07-29 2018-06-06 Arbutus Biopharma Corporation Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
CN109069520A (zh) 2016-02-25 2018-12-21 应用生物实验室公司 保护空气传播的病原体和刺激物的组合物和方法
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3439695B1 (de) 2016-04-04 2022-05-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Multivalente impfstoffe gegen tollwut- und coronaviren
CN110709065B (zh) * 2017-04-19 2023-02-10 Apa先进技术有限公司 融合脂质体、组合物、试剂盒及其治疗癌症的用途
US20200239597A1 (en) * 2017-08-09 2020-07-30 Donald Newmeyer An anti-apoptotic function of pkm2 and intracellularly expressed scfv antibodies
CN118667812A (zh) 2017-12-06 2024-09-20 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US20200113829A1 (en) * 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy
CN115697418A (zh) 2020-03-27 2023-02-03 艾维迪提生物科学公司 治疗肌营养不良的组合物和方法
CN116509818A (zh) * 2023-04-18 2023-08-01 中国人民解放军军事科学院军事医学研究院 一种低毒性的脂溶性纳米粒组合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
AU642980B2 (en) 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5705655A (en) 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
EP0728202A4 (de) 1993-11-12 1997-04-23 Univ Case Western Reserve Episomales expressionsvektor für die menschliche gentherapy
US5635380A (en) 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
WO1995032299A1 (en) 1994-05-20 1995-11-30 The Board Of Trustees Of The Leland Stanford Junior University An autonomous replication system for mammalian cells
JPH10506093A (ja) 1994-06-22 1998-06-16 メガバイオス・コーポレイション カチオン性両親媒性化合物
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5786214A (en) 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
EP0873363B1 (de) 1995-06-14 2010-10-06 The Regents of The University of California Hochaffine humane antikörper gegen tumorantigene
US20020051767A1 (en) 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6030956A (en) 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers
AU729655B2 (en) * 1996-11-12 2001-02-08 Regents Of The University Of California, The Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6248721B1 (en) * 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
EP1003895A2 (de) * 1997-07-10 2000-05-31 Hepavec AG fur Gentherapie Klonierungsvektoren für die herstellung von adenoviralen minimalviren
CA2348675A1 (en) 1997-10-24 1999-05-06 Warren Dang Methods for preparing polynucleotide transfection complexes
CN1616665B (zh) 1997-11-19 2010-10-06 乔治敦大学 定向脂质体基因送递
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
AU4090299A (en) 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
AU4089899A (en) * 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
JP4680385B2 (ja) 1998-09-11 2011-05-11 トーマス・ジェファーソン・ユニバーシティ ＲＢ２／ｐ１３０を発現するベクターによる平滑筋細胞増殖の抑制および再狭窄の防止方法

Also Published As

Publication number Publication date
EP1811036A2 (de) 2007-07-25
EP1811036B8 (de) 2011-09-21
WO2000050008A9 (en) 2002-06-27
JP2011115167A (ja) 2011-06-16
EP1154756B1 (de) 2007-01-03
JP2002537318A (ja) 2002-11-05
US7479276B1 (en) 2009-01-20
AU3703100A (en) 2000-09-14
HK1106952A1 (en) 2008-03-20
US8859274B2 (en) 2014-10-14
US20070065432A1 (en) 2007-03-22
EP1154756A2 (de) 2001-11-21
ATE511543T1 (de) 2011-06-15
EP1815848A1 (de) 2007-08-08
DE60032739T2 (de) 2007-05-24
JP5567466B2 (ja) 2014-08-06
WO2000050008A3 (en) 2000-12-21
ES2366100T3 (es) 2011-10-17
EP1811036A3 (de) 2007-08-01
EP1811036B1 (de) 2011-06-01
ATE350012T1 (de) 2007-01-15
JP4799736B2 (ja) 2011-10-26
CA2362550A1 (en) 2000-08-31
ES2278597T3 (es) 2007-08-16
CA2362550C (en) 2010-05-11
US20090191261A1 (en) 2009-07-30
PT1811036E (pt) 2011-07-11
WO2000050008A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
DE60032739D1 (de) Immunoliposome mit einem targeting-antikörperfragment zur systemischen genverabreichung
Azemar et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo
Savellano et al. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates
Lammering et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1116230T1 (el) Παραγοντες και ανταγωνιστες δεσμευσης-notch και μεθοδοι χρησης εξ' αυτων
ATE441433T1 (de) Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
EP2015758A4 (de) Verbindungen und verfahren zur modulation der expression von apo-b
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
BR0314121A (pt) Composições nutricionais
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
RU2014121820A (ru) Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
NO20055209D0 (no) Peptabody for cancerbehandling
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EP0796277A4 (de) Reagentien und verfahren zur überexpression von mütierten epidermalen wachstumsfaktorrezeptoren
MXPA01011000A (es) Analogos de poliaminas conformacionalmente restringidos como terapias para enfermedades.
Shishido et al. Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells
Stratford et al. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity
HRP20210410T1 (hr) Konjugirana antitijela prema ly75 za liječenje raka
AU784612B2 (en) Selenium-containing pro-drugs for cancer therapy
Mickisch et al. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
Gaidamakova et al. Molecular vehicle for target-mediated delivery of therapeutics and diagnostics

Legal Events

Date Code Title Description
8364 No opposition during term of opposition